Effect of EPO administration on myocardial infarct size in patients with non-STE acute coronary syndromes; results from a pilot study

Anho Liem; Anton P van de Woestijne; Erik Bruijns; Henk W O Roeters van Lennep; Job A J de Boo; Henk K van Halteren; Teun P van Es; J Wouter Jukema; Arnoud van der Laarse; Aeilko H Zwinderman; Dirk J van Veldhuisen

doi:10.1016/j.ijcard.2007.07.076

Effect of EPO administration on myocardial infarct size in patients with non-STE acute coronary syndromes; results from a pilot study

Int J Cardiol. 2009 Jan 9;131(2):285-7. doi: 10.1016/j.ijcard.2007.07.076. Epub 2007 Nov 1.

Authors

Anho Liem¹, Anton P van de Woestijne, Erik Bruijns, Henk W O Roeters van Lennep, Job A J de Boo, Henk K van Halteren, Teun P van Es, J Wouter Jukema, Arnoud van der Laarse, Aeilko H Zwinderman, Dirk J van Veldhuisen

Affiliation

¹ Oosterschelde Ziekenhuizen, Goes, The Netherlands. anho@zeelandnet.nl

PMID: 17931721
DOI: 10.1016/j.ijcard.2007.07.076

Abstract

A pilot study was performed to determine the effect of 40,000 IU Epo on myocardial damage in 51 patients with non-ST segment elevation acute coronary syndrome (non-STE ACS). No significant difference in myocardial damage was found, but an increased systolic blood pressure was noticed.

Publication types

Comparative Study
Randomized Controlled Trial

MeSH terms

Acute Coronary Syndrome / drug therapy*
Acute Coronary Syndrome / pathology*
Epoetin Alfa
Erythropoietin / administration & dosage
Erythropoietin / therapeutic use*
Humans
Injections, Intravenous
Myocardial Infarction / drug therapy*
Myocardial Infarction / pathology
Pilot Projects
Prospective Studies
Recombinant Proteins

Substances

Recombinant Proteins
Erythropoietin
Epoetin Alfa